Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Florida’s Drug Importation Plan Is Missing Cost Savings, Supply Chain Data, FDA Says

Executive Summary

Florida says new questions about its proposal show the lengths FDA will go to avoid approving it. FDA extends its deadline for acting on the application, which is the most detailed of four submitted to the agency.

You may also be interested in...



FDA To Issue Decision On Florida’s Drug Importation Proposal By October

Florida was the first of four states to submit proposals for importation of prescription drugs from Canada. PhRMA recently filed a citizen petition opposing Colorado’s proposal, which notes hurdles it is facing. Infographic compares state proposals and the drugs they plan to import.

FDA’s Orange Book Dispute Resolution Process May Grow Teeth With FTC Patent Listing Challenges

People have challenged patent listings more than 60 times in the past six years but it is up to new drug application holders to decide whether to revise or delist their submissions.

Background Music During Risk Segment Of Rx Drug Ads: FDA Explains Its Policy

Total ban on background music is unnecessary, agency says in denying KEI’s petition. FDA points to new ‘major statement’ rule and its previous letters objecting to a sponsor’s use of music in ads and says it will continue case by case analysis of ‘all of the elements’ in an ad.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel